Company facts
- Self-certified in SAM.gov
- Entity structure
- Partnership or Limited Liability Partnership
- SAM.gov registration date
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Grant awards
Latest 5 listed here. See the rest on GovTribe.
Similar vendors
| Vendor | Location | Primary NAICS |
|---|---|---|
| Cure Rare Disease | Woodbridge, CT | 541714 Research and Development in Biotechnology (except Nanobiotechnology) |
| Genetobe Inc. | Ann Arbor, MI | 541714 Research and Development in Biotechnology (except Nanobiotechnology) |
| Gigamune, Inc. | San Francisco, CA | — |
| Kinea Bio Inc. | Mukilteo, WA | 541714 Research and Development in Biotechnology (except Nanobiotechnology) |
| Bedrock Therapeutics, Inc. | Raleigh, NC | 541714 Research and Development in Biotechnology (except Nanobiotechnology) |
About the company
Myogene Bio LLC is a woman-owned small business biotechnology company located in San Diego, California, specializing in advanced gene editing therapies with a primary focus on rare genetic disorders, particularly Duchenne muscular dystrophy (DMD). Registered in SAM.gov since August 2018, the company operates as a limited liability partnership and has positioned itself as an innovative research entity developing cutting-edge gene editing technologies using CRISPR/Cas9 approaches. The company leverages technical expertise in adeno-associated virus (AAV) vector technologies and molecular biology to advance therapeutic interventions for genetic muscle disorders.
Myogene Bio LLC has secured multiple federal grant awards from prestigious research agencies, including the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), the National Center for Advancing Translational Sciences, and the Defense Health Agency. These grants, totaling approximately $1.2 million, support research focused on developing gene editing therapies for Duchenne muscular dystrophy. Specifically, the company's research involves optimizing AAV vector manufacturing processes, conducting preclinical studies in humanized mouse models to assess gene editing efficacy, and exploring innovative approaches to restore dystrophin protein function. The research aims to develop a dual AAV vector gene editing therapy that can delete specific DMD gene exons, potentially offering treatment for approximately 50% of DMD patients by restoring the gene's reading frame and generating a functional dystrophin protein. Each grant supports different aspects of research, including manufacturing process optimization, biomarker assessment, and long-term durability studies of the gene editing therapy.
Quick answers
Is Myogene Bio LLC registered in SAM.gov?
Yes. Myogene Bio LLC's SAM.gov registration is active through November 2, 2027.
What is Myogene Bio LLC's CAGE code?
Myogene Bio LLC's CAGE code is 85PB8, and its Unique Entity ID (UEI) is KEESEUSBQWL7.
What is Myogene Bio LLC's most recent federal award?
Myogene Bio LLC's most recent federal grant award is Advancing manufacturing and release testing of a gene editing therapy for duchenne muscular dystrophy (SB1AR084953), from National Insititue of Arthritis and Musculoskeletal and Skin Diseases (NIH), on August 28, 2025.
On GovTribe
See Myogene Bio LLC's full federal record
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors